Skip to content
Screener

Alumis Inc. ALMS Return on invested capital

Return on invested capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
16.7%+8.4pp
Amgen logo
AmgenAMGN
14.8%+3.6pp
Immunome logo
ImmunomeIMNM
-746.6%+212pp
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-37%—
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-42.9%—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
21.3%+21.3pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×—

Profitability

See full
Operating margin-5,364%—
Net margin-2,825.7%—
FCF margin-4,487.4%—

Returns & leverage

See full
Return on equity-64.6%—
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

nopat/invested capital=-155.3%

Based on trailing twelve months.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s return on invested capital?
Alumis Inc. (ALMS) reported return on invested capital of -155.3% in Q1 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.

Ask your AI about Alumis Inc.'s return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude